Search

A patent has been issued to Abbott Diabetes Care Inc. for systems and methods for using insulin information for meal indication. The invention aims to provide a glucose report based on large amounts of glucose data, showing patterns and analyses of the glucose history of a patient to aid in treatment considerations. The system includes a processor, non-volatile memory, and display to analyze and visually present glucose data and analytics. The method involves storing glucose data, collecting insulin timing information, identifying meal-related glucose data, performing pattern analysis, and providing treatment recommendations based on the number of rise or fall patterns detected. [Extracted from the article]

The patent application titled "Systems And Methods For Automatically Assisting Patients" discusses the use of data collection platforms in healthcare to collect and analyze healthcare-related data. These platforms can be used with medical devices to deliver therapies and monitor patient conditions. The application also proposes a triage system to prioritize patient interventions based on their condition and interaction with the system. The goal is to improve the management and assistance provided to remotely managed patient populations. The method involves identifying issues affecting patient satisfaction and providing educational material and troubleshooting recommendations to improve outcomes. [Extracted from the article]

A patent application has been submitted for a system and method that aims to improve the management and assistance provided to remotely managed patient populations. The system combines data collection with therapy, such as an implanted neuromodulator or an insulin pump, to determine a triage tier for intervention by a clinician or device representative. The method involves delivering therapy, assessing the patient's condition, receiving patient interaction, and using both the condition and interaction to assign a priority ranking for intervention. The patent application provides detailed information on the different components and processes involved in the system. [Extracted from the article]

A patent application has been submitted by inventors Apurv ULLAS Kamath and Nathanael R. Paul for a system called "Location-Aided Glycemic Control." The system aims to help individuals with diabetes manage their blood glucose levels by using sensor data to detect the user's location and predict their activities. Based on this information, the system generates recommendations to control the user's glycemic response, including administering medication if necessary. The patent application was filed by DexCom Inc. and is available online for further information. [Extracted from the article]

A patent has been issued for infusion pump methods and systems by DEKA Products Limited Partnership. The patent describes the need for wearable devices that can automatically deliver drugs over time, as well as the desire for remote control of these devices. The patent also discusses the importance of safety in medical devices. The inventors propose a medical remote controller device with a display and input switch for bolus delivery, an infusion pump system with a companion device, and a method for self-checking the integrity of the companion device. The patent also includes methods for sensing and displaying temperature warnings with the medical remote controller. [Extracted from the article]

A patent application has been submitted for an electronic module and drug delivery device that aims to improve the process of administering injections. The invention addresses challenges and risks associated with manual injection devices and discusses auto-injector devices for self-administration. The electronic module records information related to therapy and can be connected to both the drug delivery device and a computer, providing a complete therapy history. The patent application includes various embodiments of the electronic module and drug delivery device, with detailed descriptions and claims. [Extracted from the article]

The patient management system of claim 31, wherein at least one of the first physiological data or the second physiological data comprises patient symptom data. The patient management system of claim 41, wherein at least one of the first physiological data or the second physiological data comprises patient symptom data. The patient management system of claim 44, wherein the patient symptom data comprises patient-reported symptoms, each patient-reported symptom identified by one of the first or second pluralities of patients via a user interface of one of the plurality of monitoring medical devices or the plurality of therapeutic medical devices. The patient management system of claim 34, wherein the patient symptom data comprises patient-reported symptoms, each patient-reported symptom identified by one of the first or second pluralities of patients via a user interface of one of the plurality of monitoring medical devices or the plurality of therapeutic medical devices. [Extracted from the article]

More recently, some medical devices have incorporated wired and wireless data connectivity that enables a medical device to transmit data, such as blood glucose measurements, to other computing and electronic devices. In many instances, a medical device is used in a "standalone" configuration in which a user operates a medical device individually without any substantial communication between the medical device and other electronic devices. The method of claim 1, wherein the medical device cryptographic key is a shared-secret cryptographic key that is identical to a shared-secret key cryptographic stored in a memory of the medical device. [Extracted from the article]

The method of claim 6, wherein the redundancy device is the drug delivery device, and the drug delivery device is separate from the control device. The method of claim 7, wherein the comparator module is implemented on the drug delivery device, and causes the step of: communicating, by the control device, the unconfirmed drug delivery instructions to the drug delivery device. The method of claim 6, wherein the comparator module confirms the drug delivery operation by the drug delivery device when the unconfirmed drug delivery instructions and the redundant drug delivery instructions do not conflict. [Extracted from the article]

Today, there is a growing trend towards controlling personal medical devices, such as insulin infusion devices that are worn by a patient, using a non-medical device such as a patient's smart phone, laptop or tablet. "Accordingly, it is desirable to provide a medical device system, such as an insulin infusion system, that can verify whether a non-medical client device (e.g., smartphone or other smart device) is operating correctly with a wearable medical device (e.g., insulin infusion device) that is controlled by the non-medical client device. "While using non-medical devices such smartphones can provide a number of advantages, one risk from the perspective of medical device manufacturers is that a smartphone or other smart devices are a relatively open platform and not as controllable as a medical device. [Extracted from the article]

The Business Research Company The increased incidence of diabetes will support the growthof the self-monitoring blood glucose (SMBG) devices market. North America Was The Largest Region In The Self MonitoringBlood Glucose (SMBG) Devices Market In 2022 North America was the largest region in the self-monitoringblood glucose (SMBG) devices market and was worth $5.45billion in 2022, according to the self monitoring bloodglucose (SMBG) devices market analysis. [Extracted from the article]